Comera Life Sciences Holdings, Inc.
CMRA
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | 1.10M | 930.60K | 633.00K | 550.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | 1.10M | 930.60K | 633.00K | 550.20K |
| Cost of Revenue | 264.90K | 283.90K | 282.40K | 210.40K | 198.90K |
| Gross Profit | 735.50K | 815.20K | 648.40K | 422.80K | 351.40K |
| SG&A Expenses | 7.04M | 7.47M | 9.66M | 9.24M | 9.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.65M | 9.12M | 11.45M | 11.10M | 11.54M |
| Operating Income | -7.65M | -8.03M | -10.52M | -10.47M | -10.99M |
| Income Before Tax | -9.01M | -9.93M | -17.61M | -18.00M | -17.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.01 | -9.93 | -17.61 | -18.00 | -17.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.01M | -9.93M | -17.61M | -18.00M | -17.07M |
| EBIT | -7.65M | -8.03M | -10.52M | -10.47M | -10.99M |
| EBITDA | -7.55M | -7.92M | -10.42M | -10.38M | -10.89M |
| EPS Basic | -0.49 | -0.59 | -1.66 | -5.53 | -16.38 |
| Normalized Basic EPS | -0.24 | -0.30 | -0.95 | -3.38 | -10.22 |
| EPS Diluted | -0.49 | -0.59 | -1.66 | -5.53 | -16.38 |
| Normalized Diluted EPS | -0.24 | -0.30 | -0.95 | -3.38 | -10.22 |
| Average Basic Shares Outstanding | 77.99M | 70.90M | 59.89M | 41.57M | 25.07M |
| Average Diluted Shares Outstanding | 77.99M | 70.90M | 59.89M | 41.57M | 25.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |